AZD 1080Alternative Names: AZD1080
Latest Information Update: 12 Feb 2008
At a glance
- Originator AstraZeneca
- Class Antidementias
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 12 Feb 2008 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (unspecified route)
- 06 Aug 2004 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)